All In Biotech

Drug Trial Radar · NCT06447415

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Single Dose Incremental Phase Ib Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Aug 6, 2024

Primary completion

Mar 18, 2025

Study completion Jun 11, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

  • HRS-7450Drug

    HRS-7450 Injection

  • 0.9% sodium chloride injectionDrug

    0.9% sodium chloride injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptomatic Intracranial Hemorrhage within 36 hours after the start of administration, The incidence of sICHTime frame: within 36 hours after the start of administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Sun Yat sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.